• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Small Utah biotech regenerates skin, hair in pigs

June 8, 2017 By Sarah Faulkner

PolarityTeUtah-based biotech PolarityTe Inc. (NSDQ:COOL) has successfully regenerated skin and triggered hair growth in pigs with burns and abrasions. The breakthrough is a win in regenerative medicine, especially for tissue engineers hoping to help burn victims recover their skin.

The firm’s approach involves using a patient’s own healthy tissue to grow human skin as a treatment for burns and wounds.

Traditional methods to treat serious burns are limited in their effectiveness and can be very costly, PolarityTe founder & CEO Denver Lough told Reuters.

One widely-used skin graft is Vericel’s Epicel – but that product doesn’t result in functional skin.

Using wounded pigs at an animal facility in Utah, PolarityTe tested its regenerative approach. The company told the news wire that their therapy resulted in scar-less healing, stimulated the growth of hair follicles, completely covered the wound and regenerated all skin layers.

Pig skin is more complex than human skin, so successfully data in swine models is usually seen as a good sign for human trials.

The company said it is slated to begin a human trial later this year and that it hopes the cell therapy could be available a year to 18 months after the trial.

“If clinically successful, the PolarityTe platform could deliver the 1st scientific breakthrough in wound healing and reconstructive surgery in nearly half a century,” Lough said, according to Reuters.

PolarityTe added that the technology’s potential isn’t limited to skin regeneration, but could include developing fully-functional bone, muscle and cartilage.

The company told Reuters that it would be “opportunistic” with financing to support upcoming trial expenses.

COOL shares were trading at $18.16 apiece in late-afternoon trading today, up 1%.

Material from Reuters was used in this report. 

Filed Under: Featured, Preclinical Trials, Regenerative Medicine, Wound Care Tagged With: polarityte

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS